Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

(2015) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma

(2014) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer

(2014) Johanna Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program

(2014) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma

(2013) Michael Roth et al.   CANCER

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: Implications for chemotherapy-induced peripheral neuropathy

(2013) Nichole E. LaPointe et al.   NEUROTOXICOLOGY

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

(2013) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

(2012) David Ebb et al.   JOURNAL OF CLINICAL ONCOLOGY

New targets and approaches in osteosarcoma

(2012) Jonathan Gill et al.   PHARMACOLOGY & THERAPEUTICS

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer

(2010) A. A. N. Rose et al.   CLINICAL CANCER RESEARCH

Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma

(2010) Bernd Kubista et al.   INTERNATIONAL ORTHOPAEDICS

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma

(2009) Alexander J. Chou et al.   CANCER

Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion

(2009) Mizuki Tomihari et al.   EXPERIMENTAL DERMATOLOGY

Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function

(2008) S ABDELMAGID et al.   EXPERIMENTAL CELL RESEARCH

Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity

(2008) Matilda H.-C. Sheng et al.   FEBS LETTERS

Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB

(2008) Vera M. Ripoll et al.   GENE